TCRT (Alaunos Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.15
GF Value $0.69
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics FCF Margin %?

Alaunos Therapeutics TCRT -0.18% 28 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.69 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Alaunos Therapeutics ranks worse than 98.33% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Alaunos Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-1.03 Mil. Alaunos Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Alaunos Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Alaunos Therapeutics's current FCF Yield % is -59.56%.

The historical rank and industry rank for Alaunos Therapeutics's FCF Margin % or its related term are showing as below:

TCRT' s FCF Margin % Range Over the Past 10 Years
Min: -606780   Med: -25234.1   Max: -858.13
Current: -104266.67

During the past 13 years, the highest FCF Margin % of Alaunos Therapeutics was -858.13%. The lowest was -606780.00%. And the median was -25234.10%.

TCRT's FCF Margin % is ranked worse than
98.33% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs TCRT: -104266.67

Alaunos Therapeutics FCF Margin % Related Terms

Alaunos Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics FCF Margin % Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16,279.15 -1,007.80 -606,780.00 -49,710.00 -59,340.00

Alaunos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38,600.00 0.00 0.00 -18,400.00 0.00

TCRT vs ASBP, SILO, PCSA: FCF Margin % Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alaunos Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's FCF Margin % falls into.


TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Alaunos Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.967/0.005
=-59,340.00 %

Alaunos Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.031/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Alaunos Therapeutics (TCRT) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Alaunos Therapeutics and its competitors. According to the industry distribution chart, Alaunos Therapeutics ranks #943 out of 959 companies in the Biotechnology industry, placing it in the top 98.3%.
Is Alaunos Therapeutics' FCF Margin % too high?
Alaunos Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Alaunos Therapeutics ranks #943 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' FCF Margin % compare to ASBP and SILO?
According to the Biotechnology industry distribution chart, Alaunos Therapeutics ranks #943 out of 959 companies for FCF Margin %. This places Alaunos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.69, compared to a current price of $2.15 — trading 211.6% above its estimated fair value. The current FCF Margin % is 0.00%. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.15 is trading 211.6% above its estimated GF Value™ of $0.69. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • FCF Margin %: 0.00%
  • GF Value™: $0.69 vs. price of $2.15 (211.6% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.15
Price
$0.69
GF Value